TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
02 April 2024 - 1:00PM
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage
biopharmaceutical company focused on the development of T cell
receptor (TCR)-engineered T cell therapies (TCR-T) for the
treatment of patients with cancer, today announced that the
Company will present at the 23rd Annual Needham Virtual Healthcare
Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time.
A webcast of the presentation will be available
on the “Events and Presentations” section of the Company’s website
at ir.tscan.com. An archived replay of the webcast will be
available on the Company’s website for 90 days following the
event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical
company focused on the development of T cell receptor
(TCR)-engineered T cell therapies (TCR-T) for the treatment of
patients with cancer. The Company’s lead TCR-T candidates, TSC-100
and TSC-101, are in development for the treatment of patients with
hematologic malignancies to prevent relapse following allogeneic
hematopoietic cell transplantation. The Company is also developing
TCR-T candidates for the treatment of various solid tumors. The
Company has developed and continues to expand its ImmunoBank, the
Company’s repository of therapeutic TCRs that recognize diverse
targets and are associated with multiple HLA types, to provide
customized multiplex therapeutic TCR-Ts for patients with a variety
of cancers.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor
Relations857-399-9840hsavelle@tscan.com
Melissa ForstArgot
Partners212-600-1902TScan@argotpartners.com
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024